Idorsia
Update in progressIDIA.SW (Swiss)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Idorsia Ltd is a biopharmaceutical company focused on discovering, developing, and commercializing drugs for unmet medical needs in Switzerland, the U.S., Europe, Asia, and Canada. Its pipeline spans CNS, cardiovascular, immunological, and orphan diseases. It markets QUVIVIQ (daridorexant) for insomnia. Active programs include Lucerastat for Fabry disease and several early- to mid-stage assets. Collaborations: Neuro (clazosentan), Janssen (aprocitentan), Viatris (selatogrel, cenerimod). Founded 2017, Allschwil, Switzerland.
Company score
- Sentiment
- 0.31
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.31
- Governance
- 0.16
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.13
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!